Tag: LimFlow system
PROMISE II 12-month data show durable outcomes with the LimFlow system...
One-year results from the PROMISE II US pivotal trial demonstrate the durability of outcomes of transcatheter arterialisation of the deep veins (TADV) using the...
LimFlow announces agreement to be acquired by Inari Medical
LimFlow announced today that it has entered into a definitive agreement to be acquired by Inari Medical.
A press release details that, under the terms...
Results from PROMISE II pivotal trial suggest “transformational value” of deep...
Results from the PROMISE II pivotal trial investigating transcatheter arterialisation of the deep veins using the LimFlow system in so-called no-option chronic limb-threatening ischaemia...
LimFlow raises US$40 million in Series D financing
LimFlow recently announced it has closed a US$40 million (€36 million) oversubscribed Series D financing round.
A press release reports that new investors Longitude...
PROMISE I 24-month results “validate the benefits of the LimFlow system”
LimFlow SA has announced 24-month results from the PROMISE I study of the LimFlow percutaneous deep vein arterialisation system, confirming "excellent and sustained outcomes"...
LimFlow System a ‘cost-effective and high-value alternative’ to traditional therapies
Percutaneous Deep Vein Arterialisation (pDVA) with the LimFlow System offers a cost-effective and high-value alternative to traditional therapies or amputation, according to a recent...
Positive results from pilot study of LimFlow Percutaneous Deep Vein Arterialization...
LimFlow announced on 1 August 2017 publication of positive results from the pilot study of the LimFlow Percutaneous Deep Vein Arterialization System (pDVA) in...
LimFlow receives CE mark for percutaneous critical limb perfusion system
LimFlow has received CE mark for its fully percutaneous LimFlow system designed for venous arterialisation of the lower limbs in end-stage patients at risk...
